Clinical Trials
19 trialsNCT03449901 2025-12-11
ADI-PEG 20 in Combination With Gemcitabine and Docetaxel for the Treatment of Soft Tissue Sarcoma, Osteosarcoma, Ewing's Sarcoma, and Small Cell Lung Cancer
Washington University School of Medicine
Phase 2 Completed
NCT04183062 2024-11-08
BIO-11006 for Osteosarcoma and Ewing's Sarcoma Lung Metastases
Nicklaus Children's Hospital f/k/a Miami Children's Hospital
Phase 2 Withdrawn
NCT04535713 2024-07-05
GALLANT: Metronomic Gemcitabine, Doxorubicin, Docetaxel and Nivolumab for Advanced Sarcoma
Sarcoma Oncology Research Center, LLC
Phase 2 Recruiting
NCT02511132 2022-12-22
A Two-part Phase IIb Trial of Vigil (Bi-shRNAfurin and GMCSF Augmented Autologous Tumor Cell Immunotherapy) in Ewing's Sarcoma
Gradalis, Inc.
Phase 2 Completed
NCT05116800 2021-12-07
Phase 2 Study of 9-ING-41 With Chemotherapy in Sarcoma
Brown University
Phase 2 Withdrawn
NCT04906876 2021-07-28
A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas
Brown University
Phase 2 Withdrawn
NCT01593748 2020-04-06
A Phase II Trial Comparing Gemcitabine and Pazopanib Versus Gemcitabine and Docetaxel for Patients With Advanced Soft Tissue Sarcoma
Medical University of South Carolina
Phase 2 Completed
NCT01574716 2019-08-21
SOURCE
Morphotek
Phase 2 Completed
NCT00227669 2016-08-30
Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma
UNICANCER
Phase 2 Completed
NCT00887809 2016-01-25
Gemcitabine and Docetaxel With Bevacizumab in Selected Sarcoma Subtypes
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00189137 2015-12-07
Evaluation of Side Effects and Relative Activity of Two Chemotherapy Regimens in the Treatment Soft Tissue Sarcoma
University of Michigan Rogel Cancer Center
Phase 2 Completed
NCT01380275 2014-09-25
Trial of Docetaxel and Irinotecan (DI) for Recurrent or Refractory Bone and Soft Tissue Sarcomas.
National Cancer Center, Korea
Phase 2 Unknown
NCT00101127 2014-02-14
Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma
GOG Foundation
Phase 2 Completed
NCT00359333 2013-10-30
STS
National Health Research Institutes, Taiwan
Phase 2 Completed
NCT01812018 2013-03-15
Endostar + GT in Pulmonary Metastases of Soft Tissue Sarcoma
ChineseAMS
Phase 2 Unknown
NCT00004066 2013-03-07
Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00002825 2013-02-05
Docetaxel in Treating Children With Recurrent Solid Tumors
National Cancer Institute (NCI)
Phase 2 Completed
NCT00073983 2012-03-12
Gemcitabine and Docetaxel in Treating Patients With Recurrent Osteosarcoma (Closed to Accrual as of 12/21/06) or Ewing's Sarcoma or Unresectable or Locally Recurrent Chondrosarcoma
Sarcoma Alliance for Research through Collaboration
Phase 2 Completed
NCT00807261 2008-12-12
Weekly Docetaxel and Fixed-Dose Rate Gemcitabine Combination Chemotherapy
Asan Medical Center
Phase 2 Unknown